Chefer V I, Morón J A, Hope B, Rea W, Shippenberg T S
Behavioral Neuroscience Laboratory, NIH/NIDA Intramural Research Program, 5500 Nathan Shock Drive, Baltimore, MD 21224, USA.
Neuroscience. 2000;101(3):619-27. doi: 10.1016/s0306-4522(00)00417-6.
In vivo microdialysis was used to characterize basal dopamine dynamics and cocaine-evoked dopamine levels in the medial prefrontal cortex of male Sprague-Dawley rats that had previously received once daily injections of cocaine (days 1-5; 20mg/kg, i.p.) in combination with the selective kappa-opioid receptor agonist U-69593 (days 3-5; 0.32mg/kg, s.c.) or its vehicle. The influence of these treatments on [3H]dopamine uptake in medial prefrontal cortex synaptosomes was also determined. Three days following the cessation of drug treatment, animals with prior history of cocaine administration exhibited enhanced psychomotor stimulation in response to a subsequent cocaine challenge. This effect was not apparent in animals that had previously received the cocaine treatment regimen in combination with the kappa-opioid receptor agonist U-69593. Cocaine challenge increased prefrontal dopamine levels in all pretreatment groups, but cocaine-pre-exposed animals had lower cocaine-evoked dopamine levels and higher basal in vivo extraction fraction, indicative of an increase in basal dopamine uptake relative to controls. Pretreatment with U-69593 prevented these effects of cocaine. Measurement of [3H]dopamine uptake in synaptosomes revealed a significant increase in uptake three days after the cessation of cocaine treatment. No increase in uptake was observed in animals that had received the cocaine treatment regimen in combination with U-69593. These results demonstrate that the early phase of abstinence from cocaine is associated with marked alterations in medial prefrontal cortex dopamine neurotransmission and that these neuroadaptations are prevented by the activation of kappa-opioid receptors. Furthermore, they raise the possibility that mesocortical dopamine neurons may be an important neural substrate upon which kappa-opioid agonists act to prevent the development of cocaine-induced behavioral sensitization.
采用体内微透析技术,对雄性Sprague-Dawley大鼠内侧前额叶皮质的基础多巴胺动态变化以及可卡因诱发的多巴胺水平进行了表征。这些大鼠先前每天接受一次可卡因注射(第1 - 5天;20mg/kg,腹腔注射),同时联合选择性κ-阿片受体激动剂U-69593(第3 - 5天;0.32mg/kg,皮下注射)或其溶剂。还测定了这些处理对内侧前额叶皮质突触体中[3H]多巴胺摄取的影响。药物治疗停止三天后,有可卡因给药史的动物在随后接受可卡因激发时表现出增强的精神运动性兴奋。这种效应在先前接受可卡因治疗方案联合κ-阿片受体激动剂U-69593的动物中并不明显。可卡因激发使所有预处理组的前额叶多巴胺水平升高,但先前接触过可卡因的动物可卡因诱发的多巴胺水平较低,体内基础提取分数较高,这表明相对于对照组,基础多巴胺摄取增加。用U-69593预处理可预防可卡因的这些效应。突触体中[3H]多巴胺摄取的测量显示,可卡因治疗停止三天后摄取量显著增加。在接受可卡因治疗方案联合U-69593的动物中未观察到摄取量增加。这些结果表明,可卡因戒断的早期阶段与内侧前额叶皮质多巴胺神经传递的明显改变有关,并且这些神经适应性变化可通过κ-阿片受体的激活来预防。此外,它们还提出了中脑皮质多巴胺神经元可能是κ-阿片激动剂作用以预防可卡因诱导的行为敏化发展的重要神经底物的可能性。